The following video is part of our "Motley Fool Conversations" series, in which, Austin Smith, consumer goods editor and analyst, and David Williamson, health-care editor and analyst, discuss topics around the investing world.

In today's edition, they discuss how Pfizer continues to shake things up. A dividend increase is on the way, and the company is looking to spin off or sell the animal health and nutrition business and use the money to bolster its pipeline -- a pipeline that needs to absorb the loss of the worlds best selling drug Lipitor.

Editor's note: Since the filiming of this video, Pfizer has increased its dividend.

Austin Smith and David Williamson both own shares of Pfizer. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Pfizer and Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.